NCT05686070: An ongoing trial by Bayer
This trial is ongoing. It must report results 2 weeks, 3 days ago.
Full data
| Full entry on ClinicalTrials.gov | NCT05686070 |
|---|---|
| Title | A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 26, 2023 |
| Completion date | Oct. 23, 2025 |
| Required reporting date | Oct. 23, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 3, 2026 |
| Days late | None |